背景与目的:干扰素/维甲酸联合应用诱导细胞凋亡相关的基因(gene associated with retinoid-interferon-induced mortality-19,GRIM-19)属转录信号转导子与激活子3(signal transducers and activators of transcription 3,STAT3)特异性...背景与目的:干扰素/维甲酸联合应用诱导细胞凋亡相关的基因(gene associated with retinoid-interferon-induced mortality-19,GRIM-19)属转录信号转导子与激活子3(signal transducers and activators of transcription 3,STAT3)特异性抑制蛋白,STAT3及其介导的信号转导通路参与调节细胞的增殖、凋亡与分化,并介导细胞的恶性转化。本研究分析GRIM-19及其靶基因STAT3在结直肠癌组织中的表达情况,探讨GRIM-19及其靶基因产物在结直肠癌发病中的作用。方法:采用免疫组织化学染色及Western blot检测40例结直肠正常组织及癌组织中GRIM-19、STAT3、p-STAT3蛋白表达,对各表达情况与不同临床病理特征进行统计学分析。采用逆转录-聚合酶链反应(reverse transcription-polymerase chain reaction,RT-PCR)方法及测序检测结肠癌细胞系SW480及23例结直肠正常组织及癌组织中GRIM-19mRNA有无基因突变及在mRNA的表达情况。结果:在结直肠癌组织中STAT3及p-STAT3蛋白均高表达,而GRIM-19mRNA及蛋白表达在癌组织中明显低于正常组织,且GRIM-19蛋白表达水平与结直肠癌分化程度和临床分期相关(P<0.05)。GRIM-19与STAT3和p-STAT3在结直肠癌组织中表达情况呈负相关,GRIM-19基因阳性时,STAT3基因趋向阴性(χ2=9.95,P<0.01),p-STAT3基因也趋向阴性(χ2=5.10,P=0.02)。结直肠癌组织中GRIM-19mRNA无基因突变情况。结论:GRIM-19蛋白在结直肠癌组织中的低表达或缺失与结直肠癌的发生、发展及侵袭性相关,而与基因突变无关。在结直肠癌组织中存在STAT3的持续高表达和GRIM-19的低表达共存现象,可能与细胞更易发生恶性转化和异常增殖,促进了结直肠癌的发生发展相关。展开更多
目的观察穿膜融合多肽TAT-24对结肠癌细胞增殖的影响。方法观察TAT-N24对HT29细胞内蛋白表达的影响,流式细胞仪检测HT29细胞周期进程,应用BrdU掺入的方法检测TAT-N24对细胞DNA合成的影响,证实TAT-N24的抗肿瘤作用。结果 Western blot结...目的观察穿膜融合多肽TAT-24对结肠癌细胞增殖的影响。方法观察TAT-N24对HT29细胞内蛋白表达的影响,流式细胞仪检测HT29细胞周期进程,应用BrdU掺入的方法检测TAT-N24对细胞DNA合成的影响,证实TAT-N24的抗肿瘤作用。结果 Western blot结果显示TAT-N24能够有效进入细胞内,TAT-N24处理的细胞内Rb蛋白的表达无显著变化,但可见磷酸化Rb蛋白表达量显著降低。BrdU/PI双掺入法检测细胞DNA合成结果显示,对照组BrdU阳性细胞数占总细胞的比例为(52.2±1.88)%,而TAT-N24组BrdU阳性细胞数占总细胞的比例为(29.9±2.14)%,两组间比较差异有统计学意义(P<0.05)。对照组HT29细胞中G0/G1期细胞为(55.27±2.48)%,S期和G2/M期细胞数分别为(26.97±0.94)%和(17.76±1.77)%,而TAT-N24组HT29细胞G0/G1期细胞减少到(65.10±1.79)%,S期和G2/M期细胞分别为(18.49±0.68)%和(16.40±1.51)%,较对照组差异有统计学意义(P<0.05)。结论融合多肽TAT-24能有效抑制Rb蛋白磷酸化,阻滞结肠癌HT29细胞周期进程,抑制细胞DNA合成。展开更多
This study examined the synergetic effect of class ⅠA Phosphoinositide 3-kinases catalytic subunit p110β knockdown in conjunction with oxaliplatin treatment on colon cancer cells. Down-regulation of p110β by siRNA ...This study examined the synergetic effect of class ⅠA Phosphoinositide 3-kinases catalytic subunit p110β knockdown in conjunction with oxaliplatin treatment on colon cancer cells. Down-regulation of p110β by siRNA interference and oxaliplatin treatment were applied in colon cancer cell lines HT29, SW620 and HCT116. MTT assay was used to measure the inhibitory effect of p110β knockdown on the proliferation of colon cancer cell lines. SubG1 assay and Annexin-Ⅴ FITC/PI double-labeling cytometry were applied to detect cell apoptosis. And cell cycle was evaluated by using PI staining and flow cytometry. The expression of caspase 3, cleaved PARP, p-Akt, T-Akt and p110β was determined by western blotting. The results suggested that down-regulation of p110β expression by siRNA obviously reduced cell number via accumulation in G0-G1 phase of the cell cycle in the absence of notablely increased apoptosis in colon cancer cell lines HT29 and SW620 (S phase arrest in HCT116). Moreover, inhibition of p110β expression increased oxaliplatin-induced cell apoptosis and cell cycle arrest in HT29, HCT116 and SW620 cell lines. In addition, increases of cleaved caspase-3 and cleaved PARP induced by oxaliplatin treatment were determined by immunoblotting in p110β knockdown group compared with normal control group and wildtype group. It is concluded that down-regulated expression of p110β could inhibit colon cancer cells proliferation and result in increased chemosensitivity of colorectal cancer cells to oxaliplatin through augmentation of oxaliplatin-induced cell apoptosis and cell cycle arrest.展开更多
This study examined the role of regulated upon activation normal T cell expressed and secreted（RANTES） and its receptor C-C chemokine receptor type 5（CCR5） in gastric cancer metastasis and the associated mechanism...This study examined the role of regulated upon activation normal T cell expressed and secreted（RANTES） and its receptor C-C chemokine receptor type 5（CCR5） in gastric cancer metastasis and the associated mechanism.The expression of RANTES and CCR5 was detected by using immunohistochemical staining and Western blotting in the gastric cancer tissues obtained from 60 gastric cancer patients with or without lymph node metastasis（n=30 in each）.The results showed that the expression levels of RANTES and CCR5 were higher in gastric cancer with lymph node metastasis than in that without metastasis（P0.05）.The expression levels of RANTES in 30 lymph nodes with cancerous invasion were higher than in 30 normal lymph nodes（P0.05）.Chemotactic test revealed that the number of migrating gastric cancer cells（n=295.0±54.6） induced by the protein of cancer-invading lymph nodes was greater than that by the protein mixture from cancer-invading lymph nodes and RANTES antibody（n=42.5±11.6）（P0.05）.RT-PCR showed that the expression levels of the main Th1 cytokines（IL-2,γ-IFN） were lower in gastric cancer with lymph node metastasis（2.22±0.90,3.26±1.15 respectively） than in that without metastasis（3.07±1.67,4.77±1.52 respectively）（P0.05）,but the expression level of the main Th 2 cytokine（IL-10） was higher in gastric cancer with lymph nodes metastasis（6.06±2.04） than in that without metastasis（4.88±1.87）（P0.05）.It was concluded that RANTES and its receptor CCR5 may contribute to gastric cancer metastasis through influencing the balance of Th1/Th2.RANTES and CCR5 may become a marker of gastric cancer metastasis.展开更多
文摘背景与目的:干扰素/维甲酸联合应用诱导细胞凋亡相关的基因(gene associated with retinoid-interferon-induced mortality-19,GRIM-19)属转录信号转导子与激活子3(signal transducers and activators of transcription 3,STAT3)特异性抑制蛋白,STAT3及其介导的信号转导通路参与调节细胞的增殖、凋亡与分化,并介导细胞的恶性转化。本研究分析GRIM-19及其靶基因STAT3在结直肠癌组织中的表达情况,探讨GRIM-19及其靶基因产物在结直肠癌发病中的作用。方法:采用免疫组织化学染色及Western blot检测40例结直肠正常组织及癌组织中GRIM-19、STAT3、p-STAT3蛋白表达,对各表达情况与不同临床病理特征进行统计学分析。采用逆转录-聚合酶链反应(reverse transcription-polymerase chain reaction,RT-PCR)方法及测序检测结肠癌细胞系SW480及23例结直肠正常组织及癌组织中GRIM-19mRNA有无基因突变及在mRNA的表达情况。结果:在结直肠癌组织中STAT3及p-STAT3蛋白均高表达,而GRIM-19mRNA及蛋白表达在癌组织中明显低于正常组织,且GRIM-19蛋白表达水平与结直肠癌分化程度和临床分期相关(P<0.05)。GRIM-19与STAT3和p-STAT3在结直肠癌组织中表达情况呈负相关,GRIM-19基因阳性时,STAT3基因趋向阴性(χ2=9.95,P<0.01),p-STAT3基因也趋向阴性(χ2=5.10,P=0.02)。结直肠癌组织中GRIM-19mRNA无基因突变情况。结论:GRIM-19蛋白在结直肠癌组织中的低表达或缺失与结直肠癌的发生、发展及侵袭性相关,而与基因突变无关。在结直肠癌组织中存在STAT3的持续高表达和GRIM-19的低表达共存现象,可能与细胞更易发生恶性转化和异常增殖,促进了结直肠癌的发生发展相关。
文摘目的观察穿膜融合多肽TAT-24对结肠癌细胞增殖的影响。方法观察TAT-N24对HT29细胞内蛋白表达的影响,流式细胞仪检测HT29细胞周期进程,应用BrdU掺入的方法检测TAT-N24对细胞DNA合成的影响,证实TAT-N24的抗肿瘤作用。结果 Western blot结果显示TAT-N24能够有效进入细胞内,TAT-N24处理的细胞内Rb蛋白的表达无显著变化,但可见磷酸化Rb蛋白表达量显著降低。BrdU/PI双掺入法检测细胞DNA合成结果显示,对照组BrdU阳性细胞数占总细胞的比例为(52.2±1.88)%,而TAT-N24组BrdU阳性细胞数占总细胞的比例为(29.9±2.14)%,两组间比较差异有统计学意义(P<0.05)。对照组HT29细胞中G0/G1期细胞为(55.27±2.48)%,S期和G2/M期细胞数分别为(26.97±0.94)%和(17.76±1.77)%,而TAT-N24组HT29细胞G0/G1期细胞减少到(65.10±1.79)%,S期和G2/M期细胞分别为(18.49±0.68)%和(16.40±1.51)%,较对照组差异有统计学意义(P<0.05)。结论融合多肽TAT-24能有效抑制Rb蛋白磷酸化,阻滞结肠癌HT29细胞周期进程,抑制细胞DNA合成。
基金supported by grants from National Natural Science Foundation of China(No.81072431,30872472,30973496,and30800569)a grant from Innovation Founda-tion of Huazhong University of Science and Technology(No.2010MS027)+1 种基金grants of Foundation of Program973(No.2009CB521802)Special Fund for Central University Basic Scientific Research(No.2011JC062,and2011JC063)
文摘This study examined the synergetic effect of class ⅠA Phosphoinositide 3-kinases catalytic subunit p110β knockdown in conjunction with oxaliplatin treatment on colon cancer cells. Down-regulation of p110β by siRNA interference and oxaliplatin treatment were applied in colon cancer cell lines HT29, SW620 and HCT116. MTT assay was used to measure the inhibitory effect of p110β knockdown on the proliferation of colon cancer cell lines. SubG1 assay and Annexin-Ⅴ FITC/PI double-labeling cytometry were applied to detect cell apoptosis. And cell cycle was evaluated by using PI staining and flow cytometry. The expression of caspase 3, cleaved PARP, p-Akt, T-Akt and p110β was determined by western blotting. The results suggested that down-regulation of p110β expression by siRNA obviously reduced cell number via accumulation in G0-G1 phase of the cell cycle in the absence of notablely increased apoptosis in colon cancer cell lines HT29 and SW620 (S phase arrest in HCT116). Moreover, inhibition of p110β expression increased oxaliplatin-induced cell apoptosis and cell cycle arrest in HT29, HCT116 and SW620 cell lines. In addition, increases of cleaved caspase-3 and cleaved PARP induced by oxaliplatin treatment were determined by immunoblotting in p110β knockdown group compared with normal control group and wildtype group. It is concluded that down-regulated expression of p110β could inhibit colon cancer cells proliferation and result in increased chemosensitivity of colorectal cancer cells to oxaliplatin through augmentation of oxaliplatin-induced cell apoptosis and cell cycle arrest.
基金supported by a grant from Natural Sciences Foundation of Hubei Province of China (No. 2006ABA098)
文摘This study examined the role of regulated upon activation normal T cell expressed and secreted（RANTES） and its receptor C-C chemokine receptor type 5（CCR5） in gastric cancer metastasis and the associated mechanism.The expression of RANTES and CCR5 was detected by using immunohistochemical staining and Western blotting in the gastric cancer tissues obtained from 60 gastric cancer patients with or without lymph node metastasis（n=30 in each）.The results showed that the expression levels of RANTES and CCR5 were higher in gastric cancer with lymph node metastasis than in that without metastasis（P0.05）.The expression levels of RANTES in 30 lymph nodes with cancerous invasion were higher than in 30 normal lymph nodes（P0.05）.Chemotactic test revealed that the number of migrating gastric cancer cells（n=295.0±54.6） induced by the protein of cancer-invading lymph nodes was greater than that by the protein mixture from cancer-invading lymph nodes and RANTES antibody（n=42.5±11.6）（P0.05）.RT-PCR showed that the expression levels of the main Th1 cytokines（IL-2,γ-IFN） were lower in gastric cancer with lymph node metastasis（2.22±0.90,3.26±1.15 respectively） than in that without metastasis（3.07±1.67,4.77±1.52 respectively）（P0.05）,but the expression level of the main Th 2 cytokine（IL-10） was higher in gastric cancer with lymph nodes metastasis（6.06±2.04） than in that without metastasis（4.88±1.87）（P0.05）.It was concluded that RANTES and its receptor CCR5 may contribute to gastric cancer metastasis through influencing the balance of Th1/Th2.RANTES and CCR5 may become a marker of gastric cancer metastasis.
